CAJ | 학술논문

选择性增殖腺病毒 dl1520是一种新型的进入 III期临床研究的肿瘤病毒基因治疗药物,本文综述了 dl1520的发现、结构、实验研究和作用机制、临床试验研究疗效以及研究方向和展望 ,提倡使用此种肿瘤基因药物在肿瘤患者治疗及预后生存期内减少毒副反应,希望可以在提高患者生存质量上提供理论依据.
선택성증식선병독 dl1520시일충신형적진입 III기림상연구적종류병독기인치료약물,본문종술료 dl1520적발현、결구、실험연구화작용궤제、림상시험연구료효이급연구방향화전망 ,제창사용차충종류기인약물재종류환자치료급예후생존기내감소독부반응,희망가이재제고환자생존질량상제공이론의거.
Replication-selective adenovirus ONYX-015 is a new drug in viral gene therapy against tumor. We reviewed its discovery, structure, experimental study and clinical trial results,hoping to provide theoretical bases for its eventual clinical application in tumor patients,to improve their prognosis and reduce adverse effect during the therapy and ultimately,to help the patients have better quality of life.